At the heart of Novo Nordisk’s acquisition of Montreal-based Inversago Pharma is an oral agonist designed to block the receptor protein CB1, which plays an important role in metabolism and appetite regulation.
Made-in-Alberta technology is designed to make it easier for doctors to identify performance gaps in their practice, document improvements and get CME credits.
Better understanding of what triggers unpleasant or sexual dreams under anesthesia could help researchers figure out how to reduce the risk of hallucinations to keep patients and providers safe